Inhibition of Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

被引：0
|
作者：
Zhu, Ningxi [1 ]
Gu, Lubing [1 ]
Zhou, Muxiang [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2790.2790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2790
引用
收藏
页码：821A / 821A
页数：1
相关论文
共 50 条
  • [41] Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
    Ingvild Haaland
    Jill A Opsahl
    Frode S Berven
    Håkon Reikvam
    Hanne K Fredly
    Ragnhild Haugse
    Bernd Thiede
    Emmet McCormack
    Sonia Lain
    Øystein Bruserud
    Bjørn Tore Gjertsen
    [J]. Molecular Cancer, 13
  • [42] Inhibition of the PI3K/AKT/mTOR pathway overcomes resistance to ABL-directed TKI in long-term cultured acute lymphoblastic leukemia (ALL) cells
    Badura, S.
    Tesanovic, T.
    Pfeifer, H.
    Hohnloser, C.
    Serve, H.
    Ruthardt, M.
    Ottmann, O. G.
    [J]. ONKOLOGIE, 2011, 34 : 207 - 207
  • [43] Inhibition of DNA damage response pathway using combination of DDR pathway inhibitors and radiation in treatment of acute lymphoblastic leukemia cells
    Katoueezadeh, Maryam
    Pilehvari, Niloofar
    Fatemi, Ahmad
    Hassanshahi, Gholamhossein
    Torabizadeh, Seyedeh Atekeh
    [J]. FUTURE ONCOLOGY, 2021, 17 (21) : 2803 - 2816
  • [44] Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells
    Hulleman, Esther
    Kazemier, Karin M.
    Holleman, Amy
    VanderWeele, David J.
    Rudin, Charles M.
    Broekhuis, Mathilde J. C.
    Evans, William E.
    Pieters, Rob
    Den Boer, Monique L.
    [J]. BLOOD, 2009, 113 (09) : 2014 - 2021
  • [45] Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
    Badura, Susanne
    Tesanovic, Tamara
    Pfeifer, Heike
    Wystub, Sylvia
    Nijmeijer, Bart A.
    Liebermann, Marcus
    Falkenburg, J. H. Frederik
    Ruthardt, Martin
    Ottmann, Oliver G.
    [J]. PLOS ONE, 2013, 8 (11):
  • [46] PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)
    Urtishak, Karen A.
    Wang Li-San
    Teachey, David T.
    Sarah, Tasian K.
    Barrett, Jeffrey S.
    Chen, I-Ming L.
    Atlas, Susan R.
    Harvey, Richard C.
    Heerema, Nyla A.
    Carroll, Andrew J.
    Hunger, Stephen P.
    Willman, Cheryl L.
    Felix, Carolyn A.
    [J]. BLOOD, 2013, 122 (21)
  • [47] Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
    Kannan, Sankaranarayanan
    Aitken, Marisa J. L.
    Herbrich, Shelley M.
    Golfman, Leonard S.
    Hall, Mandy G.
    Mak, Duncan H.
    Burks, Jared K.
    Song, Guangchun
    Konopleva, Marina
    Mullighan, Charles G.
    Chandra, Joya
    Zweidler-McKay, Patrick A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (09) : 1615 - 1627
  • [48] Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
    Huang, Baoying
    Vassilev, Lyubomir T.
    [J]. AGING-US, 2009, 1 (10): : 845 - 854
  • [49] Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
    Cani, Alice
    Simioni, Carolina
    Martelli, Alberto M.
    Zauli, Giorgio
    Tabellini, Giovanna
    Ultimo, Simona
    McCubrey, James A.
    Capitani, Silvano
    Neri, Luca M.
    [J]. ONCOTARGET, 2015, 6 (09) : 6597 - 6610
  • [50] The effect of the PI3K/AKT pathway inhibition on leiamyosarcoma cells.
    D'Amato, GZ
    Mohapatra, S
    Jove, R
    Windham, TC
    Burns, AC
    Sullivan, D
    Muro-Cacho, C
    Letson, GD
    Pledger, WJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 818S - 818S
12345